Biofidelity

Executive Summary

Biofidelity is a UK-based genomics company focused on improving biomarker testing for cancer patients. Founded in 2019 in Cambridge, the company addresses a critical gap in oncology care: many patients do not receive the comprehensive genomic testing needed to match them with targeted therapies. By developing advanced diagnostic tools, Biofidelity aims to simplify and accelerate the detection of actionable mutations, thereby enabling more personalized treatment decisions. The company's approach leverages next-generation sequencing and AI-driven analysis to deliver accurate, cost-effective results. With the growing emphasis on precision medicine and the expanding number of targeted therapies, Biofidelity is well-positioned to capture a significant share of the molecular diagnostics market. However, as a private company with limited financial disclosures, its near-term trajectory depends on successful execution of clinical validations and commercial partnerships.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round80% success
• TBDStrategic Partnership with Major Pharma60% success
• Q4 2026Publication of Clinical Validation Study75% success